Speaker Profile
M.D., Professor and Division Head, OHSU
Biography
Dr. Shivaani Kummar is Margaret and Lester DeArmond Chair of Molecular Oncology, Division Chief of Hematology and Medical Oncology, co-Director of the Center of Experimental Therapeutics, and Deputy Director for Clinical and Translational Research, Knight Cancer Institute, Oregon Health Science University, Portland, Oregon, USA. She specializes in conducting pharmacokinetic and pharmacodynamic driven first-in-human trials tailored to make early, informed decisions regarding the suitability of novel molecular agents for further clinical investigation. She is a member of scientific planning committees of national and international professional organizations and has authored over 160 peer reviewed publications, 9 book chapters, and co-edited a book on Novel Designs of Early Phase Trials for Cancer Therapies. She is currently a member of the American Association for Cancer Research Exploratory INDPhase 0 Clinical Trials Task Force, and co-Chair of the Clinical Trials Committee, AACR Annual Meeting 2023-2024.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
Gad Getz, Broad Institute
Alex Morgan, Khosla Ventures
PMWC Award Ceremony Honoree
• Greg Brockman, President & Co-Founder, OpenAI
• Steve Wozniak, Co-Founder, Apple
Keynote
• Vinod Khosla, Khosla Ventures
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Illuminating Drug Discovery: AI Models That Learn From Biology
• Erwin Estigarribia, HEADLAMP Health
Harmonizing the Data Economy: Enabling AI Across Institutions and Therapeutic Areas
• Noah Nasser, Datma
Can AI Really Create the Next Blockbuster Drug?
• James Zou, Stanford
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Chair: Rajat Roy, PATHOMIQ INC
Closing the Loop: AI in the Messy Middle of Drug Development
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald / MIT
Is AI the New Drug?
• Michael J. Kahana, Nia Therapeutics
